RE-BVS – Piemonte Repository

Sfoglia per AUTORE
SCAMBIA G
Collezione AOU Città della Salute di Torino

Items : 5

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. in NPJ breast cancer / NPJ Breast Cancer. 2024 Feb 5;10(1):13. doi: 10.1038/s41523-024-00619-5.

2024
AOU Città della Salute di Torino

Caldara A; Fontana A; Haspinger ER; Verderame F; Franco A; Valerio MR; Beano A; Raffaele M; Criscitiello C; Curigliano G; Guarino S; Pedersini R; Strina C; La Verde N; Savastano MC; Fuso P; Paris I; Botticelli A; Carbognin L; Fabi A; Di Leone A; Tortora G; Giannarelli D; Scambia G;

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. in NPJ breast cancer / NPJ Breast Cancer. 2023 Sep 8;9(1):73. doi: 10.1038/s41523-023-00579-2.

2023
AOU Città della Salute di Torino

Fabi A; Carbognin L; Botticelli A; Paris I; Fuso P; Savastano MC; La Verde N; Strina C; Pedersini R; Guarino S; Curigliano G; Criscitiello C; Raffaele M; Beano A; Franco A; Valerio MR; Verderame F; Fontana A; Haspinger ER; Caldara A; Di Leone A; Tortora G; Giannarelli D; Scambia G;

2023
AOU Città della Salute di Torino

MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study. in Cancers / Cancers (Basel). 2023 Dec 20;16(1):41. doi: 10.3390/cancers16010041.

2023
AO Ordine Mauriziano
AOU Città della Salute di Torino

Tuninetti V; Picardo E; Vertechy L; Bergamini A; Palaia I; Artioli G; Parisi A; Scandurra G; Scollo P; Baldoni A; Malaguti P; Cassani C; Zamagni C; Pisano C; Ricotti A; Marchetti C; Turinetto M; Scotto G; Scambia G; Pignata S; Valabrega G;

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28.

2014
AOU Città della Salute di Torino

Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; et alii...